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Abstract
Background: Immunity has been suggested to be important in the pathogenesis of dementia. However, the
contribution of innate versus adaptive immunity in the development of dementia is not clear. In this study, we
aimed to investigate (1) the association between components of innate immunity (granulocytes and platelets) and
adaptive immunity (lymphocytes) with risk of dementia and (2) the association between their derived ratios
(granulocyte-to-lymphocyte ratio [GLR], platelet-to-lymphocyte ratio [PLR], and systemic immune-inflammation
index [SII]), reflecting the balance between innate and adaptive immunity, with risk of dementia.
Methods: Blood cell counts were measured repeatedly between 2002 and 2015 in dementia-free participants of
the prospective population-based Rotterdam Study. Participants were followed-up for dementia until 1 January
2016. Joint models were used to determine the association between granulocyte, platelets, and lymphocyte counts,
and their derived ratios with risk of dementia.
Results: Of the 8313 participants (mean [standard deviation] age 61.1 [7.4] years, 56.9% women), 664 (8.0%) developed
dementia during a median follow-up of 8.6 years. Doubling of granulocyte and platelet counts tended to be associated
with an increased risk of dementia (HR [95%CI] 1.22 [0.89–1.67] and 1.45 [1.07–1.95], respectively). Doubling of the
derived ratios GLR, PLR, and SII were all associated with an increased dementia risk (HR [95%CI] 1.26 [1.03–1.53], 1.27
[1.05–1.53], and 1.15 [0.98–1.34], respectively).
Conclusions: GLR, PLR, and SII are associated with an increased risk of dementia in the general population. This
supports the role of an imbalance in the immune system towards innate immunity in the pathogenesis of dementia.
Keywords: Innate immune system, Adaptive immune system, Dementia, Alzheimer’s disease, Epidemiology, Cohort
studies
Background
Dementia poses a huge burden on societies in terms of fi-
nancial costs as well as on individual patients and their
caregivers regarding suffering and grief [1]. Dementia is a
multifactorial disease, in which various pathologies inter-
act during the long pre-clinical phase, ultimately resulting
in its clinical manifestations of cognitive decline and loss
of independence. While amyloid depositions, neuronal
loss, and vascular damage have long been established as
key pathologies underlying dementia [2], recent findings
point towards a key role for the immune system [3–5].
The immune system is a highly complex system involving
multiple synergistic and antagonistic substrates, yet
broadly can be classified into two components, i.e., innate
immunity and adaptive immunity [6]. Innate immunity re-
fers to immune responses present at birth, forming a first
line of defense, whereas adaptive immunity is acquired
during life by exposure to specific antigens [7]. High activ-
ity of innate immunity can lead to disrupted neuronal in-
tegrity and ultimately to cell death [8]. Although these
components of the immune system work closely together,
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adaptive immunity is considered to be more neuroprotec-
tive than innate immunity, presumably by stimulating
phagocytosis of amyloid fibrils [9, 10].
Exact quantification of these opposing components of the
immune system is challenging and focus of ongoing re-
search, but recent work from the field of cancer research
suggests that easily obtainable laboratory measurements
may in fact capture their relative activity levels to a reliable
degree [11]. Measuring granulocytes, including the most
abundant subtype neutrophils, and platelets provides im-
portant markers of the innate immunity, whereas measur-
ing lymphocytes yields information on the adaptive
immunity [12, 13]. Furthermore, combining these measure-
ments into ratios, i.e., the neutrophil-to-lymphocyte ratio
(NLR), platelet-to-lymphocyte ratio (PLR), and systemic
immune-inflammation index (SII), is thought to even better
reflect the relative balance between innate and adaptive im-
munity [11, 14–16]. Previous work on the link between in-
nate versus adaptive immunity and dementia showed
higher NLR and PLR in dementia patients compared to
healthy individuals [17–19]. Yet, to really understand the
role of the immune system in the risk of developing de-
mentia, it is pivotal to study how these markers change dur-
ing the pre-clinical phase of the disease.
We thus investigated the longitudinal association of
markers of the innate versus adaptive immune system
with the risk of dementia. The underlying hypothesis
was that higher activity of the innate versus adaptive im-
mune system would be associated with an increased risk
of dementia. A further methodological novelty of our
study was the use of joint modeling that enabled us to
study the longitudinal evolution of the various markers
during the pre-clinical phase in conjunction with sur-
vival analyses.
Methods
Study population
The present study is embedded in the Rotterdam Study, a
prospective population-based cohort study in Rotterdam,
the Netherlands. The Rotterdam Study started in 1990
with 7983 persons (response of 78%) aged ≥ 55 years and
residing in the district Ommoord, a suburb of Rotterdam.
This first subcohort (RS-I) was extended with a second
subcohort (RS-II) in 2000, consisting of 3011 persons
(response of 67%), and with a third subcohort (RS-III) in
2006, composed of 3932 persons aged ≥ 45 years (response
of 65%). The design of the Rotterdam Study has been
described in detail previously [20]. In brief, participants
were examined in detail at study entry and at follow-up
visits every 3 to 5 years. They were interviewed at home by
a trained research nurse, followed by two visits at the re-
search facility for additional interviewing, laboratory
assessments, imaging, and physical examinations.
The Rotterdam Study was approved by the Medical
Ethics Committee of Erasmus Medical Center and by
the board of The Netherlands Ministry of Health, Wel-
fare, and Sports. A written informed consent was
obtained from all participants.
Laboratory tests for granulocytes, platelets, and lympho-
cytes were introduced from 2002 onwards, corresponding
with the following assessment rounds in the Rotterdam
Study (baseline in this study): i.e., fourth round of RS-I, sec-
ond round of RS-II, and first round of RS-III, comprising
9994 participants. From these 9994 eligible participants, we
excluded those without complete baseline blood measure-
ments (n = 1288). Of the remaining participants, we ex-
cluded those with a history of dementia (n = 52),
participants who were insufficiently screened for dementia
(n = 62), and those without informed consent to assess
medical records during follow-up (n = 39). Lastly, we ex-
cluded participants with missing apolipoprotein E (APOE)
genotype (n = 240), resulting in 8313 participants for
analysis (flowchart in Fig. 1).
Assessment of blood cell counts and their derived ratios
Fasting blood samples were taken during each visit at the
research center with a maximum of three visits during
follow-up. Full blood count measurements were performed
using the COULTER® Ac·T diff2™ Hematology Analyzer
(Beckman Coulter, San Diego, CA, USA) directly after
Fig. 1 Flowchart participants for analysis association between blood cell counts, and their derived ratios, and dementia. Abbreviations: APOE,
apolipoprotein E
Willik et al. Journal of Neuroinflammation           (2019) 16:68 Page 2 of 9
blood sample drawn. Laboratory measurements included
absolute granulocyte, platelet, and lymphocyte counts in
109 per liter.
Since neutrophil counts were not available, we used
granulocyte count as a reliable proxy given that these
are the most abundant subtype of neutrophils [21, 22].
The granulocyte-to-lymphocyte ratio (GLR) and PLR
were calculated as the ratio of granulocyte count to
lymphocyte count and as the ratio of platelet count to
lymphocyte count, respectively. The SII was defined as
platelet count times the GLR.
Assessment of dementia
Participants were screened for dementia at baseline and
subsequent center visits with the Mini-Mental State
Examination and the Geriatric Mental Schedule organic
level [23]. Those with a Mini-Mental State Examination
score < 26 or Geriatric Mental Schedule score > 0 under-
went further investigation and informant interview,
including the Cambridge Examination for Mental Disor-
ders of the Elderly. The entire cohort was continuously
under surveillance for dementia through electronic link-
age of the study database with medical records from
general practitioners and the regional institute for out-
patient mental health care. Available information on
clinical neuroimaging was used when required for diag-
nosis of dementia subtype. A consensus panel led by a
consultant neurologist established the final diagnosis ac-
cording to standard criteria for dementia (Diagnostic
and Statistical Manual of Mental Disorders III-revised),
Alzheimer’s disease (AD; National Institute of Neuro-
logical and Communicative Disorders and Stroke and the
Alzheimer’s Disease and Related Disorders Association),
and vascular dementia (National Institute of Neurological
Disorders and Stroke and Association Internationale pour
la Recherché et l’Enseignement en Neurosciences).
Follow-up until 1 January 2016 was virtually complete
(93.8% of potential person-years observed).
Other measurements
We assessed education and smoking by interview. Educa-
tion level was classified into primary education, lower
(lower general education, intermediate general education,
or lower vocational education), intermediate (intermediate
vocational education or higher general education), or
higher (higher vocational education or university). Smok-
ing status was categorized as never, former, or current
smoker. Body mass index (BMI) was computed from mea-
surements of height and weight (kg/m2). Diabetes mellitus
was defined as use of antidiabetic medication, fasting
serum glucose level ≥ 7.1mmol/L, or random serum glu-
cose level ≥ 11.1mmol/L [24]. History of stroke was
assessed by interview and verified by reviewing medical
records [25]. APOE genotype was determined using
polymerase chain reaction on coded DNA samples in RS-I
and with a bi-allelic TaqMan assay in the two extensions
(RS-II and RS-III) [26, 27]. APOE ε4 carrier status was de-
fined as carrier of one or two APOE ε4 alleles.
Statistical analysis
We associated the different blood cell counts and their
derived ratios with the risk of all-cause dementia using
the framework of joint models for longitudinal and sur-
vival data. In this way, we are able to account for the en-
dogenous nature (i.e., blood cell counts can be measured
with error during follow-up and their values at any time
point can be affected by an event occurring at an earlier
time point) [28] and the correlations in the repeated
measurements of granulocyte, platelet, and lymphocyte
counts [29].
In order to normalize the skewed distribution of gran-
ulocyte, platelet, and lymphocyte counts, and their derived
ratios, we used a natural logarithmic transformation. Haz-
ard ratios (HRs) with 95% confidence intervals (CIs) were
obtained from the joint models, using the piecewise-con-
stant baseline hazard, and multiplied with log(2), providing
a HR for doubling of the blood cell counts and their ratios.
We computed two nested models: model I was adjusted
for baseline age (continuous, centered as age minus mean
age) and sex; model II was additionally adjusted for educa-
tion, smoking status, BMI (continuous), diabetes mellitus,
history of stroke, and APOE ε4 carrier status. For assess-
ment of the association between the individual compo-
nents of the ratios and dementia, we repeated analyses
with adjustment for the baseline blood cell counts of the
remaining two blood cell types (for instance, the associ-
ation of granulocyte count with dementia was adjusted for
platelet and lymphocyte counts). Follow-up time was used
as timescale and started at the first laboratory assessment
until the date of all-cause dementia diagnosis, death, loss
to follow-up, or 1 January 2016, whichever came first.
Censoring participants at date of death allowed us to com-
pute cause-specific HRs.
In sensitivity analyses, we repeated all analyses using age
as timescale instead of follow-up time to account for po-
tential residual confounding by age and to minimize po-
tential effects of left truncation. We additionally censored
for stroke events during follow-up to preclude that the ob-
served effect may be driven by incident strokes that oc-
curred before dementia diagnosis. Moreover, we
investigated the association between the ratios and AD or
vascular dementia separately. Lastly, we explored effect
modification by stratifying by median age, sex, smoking
status, diabetes mellitus, and APOE ε4 carrier status.
Multiple imputation was used for missing covariates
(maximum of 0.99%), with five imputed datasets based on
other covariates and the outcome. Rubin’s method was used
for pooled HRs and 95% Cis [30]. Two-sided P < .05 was
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considered statistically significant. Statistical analyses were
performed using the R packages “survival”, “nlme”, “JM”,
and “JMbayes” in RStudio Version 3.3.2 [28, 29, 31, 32].
Results
Characteristics of included and excluded study participants
are presented in Table 1. An overview of the median blood
cell counts and blood cell-based ratios per assessment
round is shown in Additional file 1: Table S1. Mean age of
included study participants was 61.1 years and 56.9% were
women. During a median follow-up of 8.6 years (70,273
person-years), 664 participants developed all-cause demen-
tia (543 AD, 31 vascular dementia) with an incidence rate
of 9.4 (95% CI, 8.7–10.2) per 1000 person-years.
Higher levels of granulocytes reflecting higher innate
immunity were associated with an increased risk of de-
mentia, but only after correcting for the platelet and
lymphocyte counts (HR for doubling granulocyte count
[95% CI] = 1.33 [0.99–1.79], Table 2). Doubling of
platelets was associated with an increased risk of demen-
tia (HR [95% CI] = 1.48 [1.11–1.96]). Regarding adaptive
immunity, higher levels of lymphocytes were associated
with a decreased risk of dementia (HR for doubling
lymphocyte count [95% CI] = 0.80 [0.64–0.99]).
Higher levels of GLR, PLR, and SII were associated with
an increased dementia risk (HR [95% CI] for doubling
GLR = 1.34 [1.10–1.63]; for PLR = 1.29 [1.08–1.55]; for
SII = 1.18 [1.02–1.39], respectively (Table 2)). Risk estimates
were comparable when using the adjusted model and when
using age as timescale instead of follow-up time.
Censoring for stroke did not meaningfully change the
risk estimates (Table 3). Higher levels of platelets showed
a slightly stronger association with AD compared with
all-cause dementia, while the association with granulo-
cytes was less pronounced for AD. Risk estimates for
all-cause dementia and AD were comparable for the ra-
tios. For vascular dementia, risk estimates regarding the
individual blood cell components and their derived ratios
Table 1 Baseline characteristics of the included and excluded study participants
Characteristic Included participants
(N = 8313)
Excluded participants
(N = 1528)#
No blood measurements (N = 1288) Unknown APOE genotype (N = 240)
Age, year, mean (SD) 61.1 (7.4) 72.6 (11.8) 61.7 (8.2)
Women 4729 (56.9) 845 (65.6) 160 (66.7)
Education
Primary 908 (11.0) 233 (18.4) 25 (11.7)
Lower 3329 (40.3) 537 (42.4) 95 (44.4)
Intermediate 2429 (29.4) 336 (26.5) 57 (26.7)
Higher 1588 (19.2) 161 (12.7) 37 (17.3)
Body mass index, kg/m2, mean (SD) 27.6 (4.3) 27.6 (4.5) 28.2 (4.8)
Smoking status
Current 1595 (19.3) 308 (24.4) 57 (24.5)
Former 4191 (50.7) 550 (43.6) 106 (45.5)
Diabetes mellitus 501 (6.0) 136 (10.7) 15 (6.3)
History of stroke 305 (3.7) 54 (4.2) 11 (4.6)
APOE ε4 carrier status 2328 (28.0) 244 (30.8)
Blood cell types, 109/L, median (IQR)
Granulocytes 3.8 (1.6) 4.0 (1.7)
Platelets 263 (84) 277 (87)
Lymphocytes 2.2 (0.8) 2.3 (0.9)
Blood cell-based ratios, median (IQR)
Granulocyte-to-lymphocyte ratio 1.7 (0.9) 1.7 (0.8)
Platelet-to-lymphocyte ratio 120 (55) 119 (54)
Systemic immune-inflammation index 455 (280) 473 (312)
Abbreviations: APOE apolipoprotein E, IQR interquartile ratio, N number of participants, SD standard deviation
Values are shown before multiple imputation and therefore not always add up to 100%
Data are presented as number (percentage) of participants unless otherwise indicated
#Excluded participants in this table only include those participants who were excluded due to no complete blood measurements or unknown APOE ε4
carrier status
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were more pronounced than for all-cause dementia, but
small numbers led to wider confidence intervals (n = 31).
Stratified analyses showed that the association be-
tween the ratios and dementia was particularly pro-
nounced in participants aged below the median age of
65.4 years, women, and non-smokers (Fig. 2). How-
ever, formal interaction terms did not reach statistical
significance. Also, no significant effect modification
was observed across different strata of these variables
for the association between granulocyte, platelet, and
lymphocyte counts, and risk of dementia (Fig. 3).
Discussion
In this population-based study, we found that higher
levels of granulocyte and platelet counts are related to
an increased risk of dementia, whereas a higher lympho-
cyte count is associated with a decreased dementia risk.
Furthermore, higher levels of their derived ratios, i.e.,
GLR, PLR, and SII, are associated with an increased risk
of all-cause dementia, including its subtype AD and even
more with vascular dementia.
Activation of the immune systems can result in inflam-
mation by production of different cytokines [33]. These cy-
tokines can act as a link between the innate and the
adaptive immune system, having pro- or anti-inflammatory
effects depending on the type of cytokine [34]. A recent
meta-analysis of 175 studies suggests that AD is accompan-
ied by an inflammatory response and that this can be
reflected by a variety of systemic cytokines, for instance
interferon-γ, interleukin (IL)-2, and in particular IL-6, of
Table 2 Association between blood cell counts and derived ratios, and risk of all-cause dementia
Laboratory assessment# All-cause dementia
(n/N = 664/8313)
Model I Model II
HR (95% CI) HR (95% CI)
Granulocytes 1.14 (0.87–1.50) 1.07 (0.80–1.43)
Corrected for platelets and lymphocytes 1.33 (0.99–1.79) 1.22 (0.89–1.67)
Platelets 1.48 (1.11–1.96)* 1.43 (1.08–1.90)*
Corrected for granulocytes and lymphocytes 1.48 (1.10–2.00)* 1.45 (1.07–1.95)*
Lymphocytes 0.80 (0.64–0.99)* 0.81 (0.64–1.03)
Corrected for granulocytes and platelets 0.76 (0.61–0.96)* 0.78 (0.62–1.00)
Granulocyte-to-lymphocyte ratio 1.34 (1.10–1.63)* 1.26 (1.03–1.53)*
Platelet-to-lymphocyte ratio 1.29 (1.08–1.55)* 1.27 (1.05–1.53)*
Systemic immune-inflammation index 1.18 (1.02–1.39)* 1.15 (0.98–1.34)
Abbreviations: CI confidence interval, HR hazard ratio, n number of incident dementia events, N number of participants for analysis. Model I is adjusted for age and
sex. Model II is adjusted for age, sex, education, smoking status, body mass index, diabetes mellitus, history of stroke, and APOE4 ε4 carrier status
#All types of blood cells and their derived ratios were natural logarithmic transformed
*Indicates statistically significant result
Table 3 Association between blood cell counts derived ratios, and risk of all-cause dementia and dementia subtypes
Laboratory assessment# All-cause dementia, censored for stroke
(n/N = 579/8008)†
Alzheimer’s disease
(n/N = 543/8313)
Vascular dementia
(n/N = 31/8313)
HR (95% CI) HR (95% CI) HR (95% CI)
Granulocytes 1.13 (0.83–1.56) 1.03 (0.75–1.42) 1.99 (0.52–7.55)
Corrected for platelets and lymphocytes 1.36 (0.96–1.93) 1.12 (0.79–1.58) 1.92 (0.44–8.41)
Platelets 1.45 (1.07–1.96)* 1.59 (1.17–2.17)* 3.86 (1.02–14.6)*
Corrected for granulocytes and lymphocytes 1.47 (1.07–2.02)* 1.63 (1.18–2.27)* 3.39 (0.84–13.7)
Lymphocytes 0.80 (0.62–1.02) 0.85 (0.66–1.10) 0.76 (0.25–2.30)
Corrected for granulocytes and platelets 0.76 (0.58–0.98)* 0.81 (0.62–1.06) 0.64 (0.20–2.03)
Granulocyte-to-lymphocyte ratio 1.33 (1.07–1.65)* 1.17 (0.95–1.46) 1.85 (0.74–4.62)
Platelet-to-lymphocyte ratio 1.31 (1.07–1.60)* 1.30 (1.06–1.60)* 1.99 (0.82–4.81)
Systemic immune-inflammation index 1.19 (1.01–1.41)* 1.15 (0.97–1.37) 1.77 (0.87–3.63)
Abbreviations: CI confidence interval, HR hazard ratio, n number of incident dementia events, N number of participants for analysis. Models are adjusted for age,
sex, education, smoking status, body mass index, diabetes mellitus, history of stroke, and APOE4 ε4 carrier status
#All types of blood cells and their derived ratios were natural logarithmic transformed
†Number of participants for analysis is 8313 minus participants with a history of stroke (n = 305)
*Indicates statistically significant result
Willik et al. Journal of Neuroinflammation           (2019) 16:68 Page 5 of 9
which dysregulation has been associated with multiple
chronic inflammatory diseases [35, 36]. It is now recog-
nized that systemic inflammation can trigger or ex-
acerbate the inflammatory environment of the brain,
thereby contributing to chronic neuroinflammation
and neurodegeneration [37]. A plausible explanation for
the occurrence of this chronic neuroinflammation in (pre)-
demented individuals involves a disruption of a process
called resolution [38]. Resolution is an active process that
halts the acute phase of inflammation and restores tissue
homeostasis. The acute inflammatory phase is usually initi-
ated in response to infection, neoplasia, tissue injury, or
other major homeostatic stressors. This phase is accom-
panied by the increased release of pro-inflammatory medi-
ators such as prostaglandins, leading to leukocyte
recruitment. Normally, resolution would clear the re-
cruited granulocytes [39]. However, it has been shown that
failure of resolution, induced by any chronic inflammatory
state, is associated with an overactive innate immune sys-
tem, resulting in the development of chronic inflammation,
which could subsequently lead to AD [38, 40, 41].
Our finding that an increase in the granulocyte count,
resulting in a higher GLR and SII, is associated with an
increased risk of dementia could therefore support the role
of insufficient resolution in the pathogenesis of dementia.
Only few studies examined the interplay between the in-
nate and adaptive immunity by studying levels of these
blood cell-based ratios in dementia patients. Two
cross-sectional studies showed that NLR and PLR were ele-
vated in AD patients compared to dementia-free controls
[17, 18]. In contrast, a longitudinal study assessing the tra-
jectory of NLR found no significant difference in its longi-
tudinal evolution between AD patients and dementia-free
participants [19]. Although they examined differences be-
tween AD patients and dementia-free controls, they did not
investigate the risk of developing dementia in dementia-free
participants in relation to their levels of NLR. In the present
study, we did take the time until dementia into account by
a joint modeling approach and were therefore able to assess
the risk of dementia in relation to the change of blood cell
counts and their derived ratios.
Interestingly, recent evidence shows that the NLR and
PLR are partly genetically determined with 36% estimated
heritability for NLR and 64% for PLR in a healthy
population [42]. Moreover, different single-nucleotide
polymorphisms (SNPs) identified through genome-wide
Fig. 2 Forest plots of the association of the GLR, PLR, and SII, and risk of dementia. Hazard ratios are shown in logarithmic scale with stratification
by median age, sex, smoking status, diabetes mellitus, and APOE ε4 carrier status. Abbreviations: APOE, apolipoprotein E; GLR, granulocyte-to-
lymphocyte ratio; n, number of incident dementia events; N, number of participants for analysis; PLR, platelet-to-lymphocyte ratio; SII, systemic
immune-inflammation index
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association study (GWAS) were significantly related to the
PLR phenotype, but not to NLR [43]. Importantly, some
but not all of these SNPs were also related to platelet, indi-
cating that these SNPs capture the interplay between
platelets and lymphocytes. Thus far, no GWAS for SII has
been performed. Exploring the dementia risk by genetic-
ally predicted blood cell-based ratios may provide more
insight in the causal role of immunity in dementia.
Strengths of our study include the population-based set-
ting and the thorough follow-up for dementia. Another
strength is the prospective design of this study, with the
blood cell counts being measured at multiple time points.
Using an innovative statistical method, we combined these
repeated measurements with dementia as survival outcome.
Moreover, we used blood cell counts and their derived ra-
tios, which are low-cost and easy to implement in the clinic
and other research settings. Although these ratios are
proven to be associated with chronic systemic inflamma-
tion, we need to emphasize that it is unknown whether
higher levels of GLR, PLR, and SII are functional and cause
higher levels of pro-inflammatory cytokines. To identify the
actual involved immune cell populations, determination of
different cytokines is still needed. Furthermore, the innate
and adaptive immune systems are overlapping, making it
difficult to completely distinguish their separate effects. In
addition, we used the granulocyte count as proxy for the
neutrophil count. Although the relative proportion of neu-
trophils compared to eosinophils and basophils may be
lower in persons with several specific diseases such as para-
sitic infections, asthma, or immune diseases, neutrophils
are generally the most important subtype of granulocytes. If
anything, misclassification of the granulocytes would be
non-differential and would therefore lead to underestima-
tion of the estimates [11]. In addition, we cannot rule out
reversed causality, i.e., that dementia is subclinical at time
of the laboratory assessments and causes higher levels of
GLR, PLR, and SII. Lastly, we did not have the power to
study other neurodegenerative diseases beyond dementia,
such as Parkinson’s disease or amyotrophic lateral sclerosis.
It would be interesting for future studies to also investigate
the relation between inflammation and these diseases.
Conclusions
In conclusion, higher levels of the ratios GLR, PLR, and
SII are associated with an increased risk of developing de-
mentia in the general population. Higher activation of the
Fig. 3 Forest plots of the association of granulocytes, platelets, and lymphocytes, and the risk of dementia. Hazard ratios are shown in logarithmic
scale with stratification by median age, sex, smoking status, diabetes mellitus, and APOE ε4 carrier status. Abbreviations: APOE, apolipoprotein E; n,
number of incident dementia events; N, number of participants for analysis
Willik et al. Journal of Neuroinflammation           (2019) 16:68 Page 7 of 9
innate immune system reflected by higher levels of granu-
locytes and platelets is associated with an increased
dementia risk, while the adaptive immune system is sug-
gested to be more neuroprotective. These findings support
the role of dysregulation of the immune systems in the
pathogenesis of dementia. Further studies are warranted
to assess during which phase of the pathogenesis of de-
mentia immunity is involved and to assess causality in
order to develop prevention and therapeutic strategies.
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